Suggested remit: To appraise the clinical and cost effectiveness of Betula verrucosa (Itulazax 12 SQ-Bet) within its marketing authorisation for treating severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years